[Amyloidosis in patients undergoing long-term hemodialysis: elucidation of etiological mechanism and therapeutic stratigy].
Shimojyo
Fumitake
F
D000682:Amyloid / Q000378:metabolism*; D000686:Amyloidosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D001057:Apolipoproteins E / Q000502:physiology; D017127:Glycation End Products, Advanced / Q000502:physiology; D017583:Hemodiafiltration; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D016030:Kidney Transplantation; D011509:Proteoglycans / Q000502:physiology; D006435:Renal Dialysis / Q000009:adverse effects* / Q000295:instrumentation; D000683:Serum Amyloid P-Component / Q000502:physiology; D013514:Surgical Procedures, Operative; D001613:beta 2-Microglobulin / Q000378:metabolism*
D000682:Amyloid; D001057:Apolipoproteins E; D017127:Glycation End Products, Advanced; D011509:Proteoglycans; D000683:Serum Amyloid P-Component; D001613:beta 2-Microglobulin